A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis

A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis
Recruiting
18 years - 93 years
All
Phase 1
2 participants needed
1 Location

Brief description of study

This study is being done to learn more about the safety of an investigational drug called ATYR1923, and to find out more about the effects of different doses of this drug on the lungs of people who have pulmonary sarcoidosis. "Investigational" means that it is not approved by the United States Food and Drug Administration. Participants will be assigned at random to receive either the study drug or placebo. A placebo is a harmless inactive substance. The study drug/placebo is given over 60 minutes intravenously (in your vein). Participation will last about 6 months and requires about 12 visits to Penn.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: sarcoidosis
  • Age: 18 years - 93 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832623

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.